NanoVibronix, Inc. Stock

$0.93

2.52%

Nasdaq, Jul 03, 10:30 pm CET

ISIN

US63008J1088

Symbol

NAOV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

NanoVibronix, Inc. Stock price

$0.93

-456.69 99.80% 5Y

Nasdaq, Closing price Thu, Jul 03 2025

-0.02 2.52%

ISIN

US63008J1088

Symbol

NAOV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$2.4m

Enterprise Value

$5.6m

Net debt

$3.2m

Cash

$600.0k

Shares outstanding

730.0k

Valuation (TTM | estimate)

P/E

negative | -

P/S

0.9 | -

EV/Sales

2.1 | -

EV/FCF

negative

P/B

0.0

Financial Health

Equity Ratio

17.3%

Return on Equity

-590.9%

ROCE

-13.6%

ROIC

-12.5%

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$2.7m | -

EBITDA

$-4.9m | -

EBIT

$-4.9m | -

Net Income

$-5.6m | -

Free Cash Flow

$-3.3m

Growth (TTM | estimate)

Revenue

-6.7% | -

EBITDA

-64.4% | -

EBIT

-64.9%

Net Income

-75.3% | -

Free Cash Flow

-10.4%

EPS

$-9.0

FCF per Share

$-4.5

Short interest

30.8%

Employees

Rev per Employee

$80.0k

As a Free StocksGuide user, you can view scores for all 6,966 stocks worldwide.

Get Started for Free Today

NanoVibronix, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a NanoVibronix, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a NanoVibronix, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from NanoVibronix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2.66 2.66	7% 7% 100%
- Direct Costs	1.45 1.45	63% 63% 55%
Gross Profit	1.21 1.21	39% 39% 45%
- Selling and Administrative Expenses	4.76 4.76	2% 2% 179%
- Research and Development Expense	1.32 1.32	428% 428% 50%
EBITDA	-4.85 -4.85	64% 64% -182%
- Depreciation and Amortization	0.02 0.02	- 1%
EBIT (Operating Income) EBIT	-4.87 -4.87	65% 65% -183%
Net Profit	-5.61 -5.61	75% 75% -211%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

NanoVibronix, Inc. Stock News

Neutral

Business Wire

●

10 days ago

NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the official launch of a next-generation robotic development initiative within its ENvue Medical (“ENvue” or “ENvue Medical”) division. The new platform, ENvue Drive™, is being developed to automate ele...

Neutral

Business Wire

●

12 days ago

NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division (“ENvue” or “ENvue Medical”). The systems, whi...

Neutral

Business Wire

●

25 days ago

ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical” or “ENvue”), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled “Insertion Device Positioning Guida...

More NanoVibronix, Inc. News

Company Profile

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. It targets wound healing and pain therapy, and can be administered at home, without the assistance of medical professionals. Its products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, United Kingdom, European Union, India, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Melville, NY.

Head office	United States
CEO	Brian Murphy
Employees	31
Founded	2003
Website	nanovibronix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now